These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36861451)

  • 1. Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.
    Xian S; Zhu J; Wang Y; Song H; Wang H
    Drug Deliv; 2023 Dec; 30(1):2183821. PubMed ID: 36861451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
    Li S; Xie A; Li H; Zou X; Zhang Q
    J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
    Sann H; Erichsen Jv; Hessmann M; Pahl A; Hoffmeyer A
    Life Sci; 2013 Apr; 92(12):708-18. PubMed ID: 23399699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats.
    Varshosaz J; Emami J; Fassihi A; Tavakoli N; Minaiyan M; Ahmadi F; Mahzouni P; Dorkoosh F
    Int J Colorectal Dis; 2010 Oct; 25(10):1159-65. PubMed ID: 20669022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A budesonide prodrug accelerates treatment of colitis in rats.
    Cui N; Friend DR; Fedorak RN
    Gut; 1994 Oct; 35(10):1439-46. PubMed ID: 7959202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis.
    Nolen H; Fedorak RN; Friend DR
    J Pharm Sci; 1995 Jun; 84(6):677-81. PubMed ID: 7562403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression.
    Seoudi SS; Allam EA; El-Kamel AH; Elkafrawy H; El-Moslemany RM
    Drug Deliv Transl Res; 2023 Nov; 13(11):2930-2947. PubMed ID: 37184747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
    Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
    Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Krill Oil-Incorporated Liposomes As An Effective Nanovehicle To Ameliorate The Inflammatory Responses Of DSS-Induced Colitis.
    Kim JH; Hong SS; Lee M; Lee EH; Rhee I; Chang SY; Lim SJ
    Int J Nanomedicine; 2019; 14():8305-8320. PubMed ID: 31806959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
    Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
    Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smart Responsive Quercetin-Conjugated Glycol Chitosan Prodrug Micelles for Treatment of Inflammatory Bowel Diseases.
    Shen C; Zhao L; Du X; Tian J; Yuan Y; Jia M; He Y; Zeng R; Qiao R; Li C
    Mol Pharm; 2021 Mar; 18(3):1419-1430. PubMed ID: 33522827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis.
    Varshosaz J; Emami J; Tavakoli N; Fassihi A; Minaiyan M; Ahmadi F; Dorkoosh F
    Int J Pharm; 2009 Jan; 365(1-2):69-76. PubMed ID: 18804521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and development of liposomes for colon targeted drug delivery.
    Gupta AS; Kshirsagar SJ; Bhalekar MR; Saldanha T
    J Drug Target; 2013 Feb; 21(2):146-60. PubMed ID: 23373543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
    Klotz U; Schwab M
    Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
    Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
    J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
    Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
    Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model.
    Leonard F; Ali H; Collnot EM; Crielaard BJ; Lammers T; Storm G; Lehr CM
    ALTEX; 2012; 29(3):275-85. PubMed ID: 22847255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.